Search

Displaying results 1681 - 1690 of 10000 in total
  1. Pathway

    Lisdexamfetamine Dopamine Reuptake Inhibitor Action Pathway

    smpdb.ca/view/SMP0126990
    Drug action

    Lisdexamfetamine, known commonly as Vyvanse, is a prodrug of amphetamine paired with lysine and used mainly for treating ADHD and binge eating disorders. The drug was engineered to be abuse-resistant with a delayed release. ADHD is cause...

    Drugs: Pyridoxal phosphate · Tyrosine · ATP · Dopamine · Levodopa · Lisdexamfetamine +4 more
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
  2. Pathway

    Dextroamphetamine Dopamine Reuptake Inhibitor Action Pathway

    smpdb.ca/view/SMP0126994
    Drug action

    Dextroamphetamine, known commonly as Adderall, is a drug related to amphetamine and is used mainly for treating ADHD and narcolepsy. The drug was approved by the FDA in 2001 for treating ADHD, but the exact mechanisms for its effects are...

    Drugs: Pyridoxal phosphate · Tyrosine · ATP · Dopamine · Levodopa · Calcium +4 more
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
  3. Pathway

    Serdexmethylphenidate Dopamine Reuptake Inhibitor Action Pathway

    smpdb.ca/view/SMP0127003
    Drug action

    Serdexmethylphenidate, known commonly combined with dexmethylphenidate as Azstarys, is a prodrug of dexmethylphenidate (CNS stimulant) used for first-line treatment of ADHD. ADHD is caused by an abnormality in the dopamine transporter ge...

    Drugs: Pyridoxal phosphate · Tyrosine · ATP · Dopamine · Levodopa · Calcium +4 more
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
  4. Pathway

    Dexmethylphenidate Dopamine Reuptake Inhibitor Action Pathway

    smpdb.ca/view/SMP0127004
    Drug action

    Dexmethylphenidate, known commonly combined with Serdexmethylphenidate as Azstarys, is a form of methylphenidate (CNS stimulant) used for first-line treatment of ADHD. ADHD is caused by an abnormality in the dopamine transporter gene (DA...

    Drugs: Pyridoxal phosphate · Tyrosine · ATP · Dopamine · Levodopa · Calcium +4 more
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
  5. Pathway

    Sibutramine Dopamine Reuptake Inhibitor Action Pathway

    smpdb.ca/view/SMP0127006
    Drug action

    Sibutramine, commonly known as Meridia or Reductil, is a norepinephrine, serotonin and dopamine reuptake inhibitor used for the treatment of obesity. This drug was withdrawn from US and Canadian markets for increased risk of heart attack...

    Drugs: Pyridoxal phosphate · Tyrosine · ATP · Dopamine · Sibutramine · Levodopa +4 more
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
  6. Drug

    Canagliflozin

    go.drugbank.com/drugs/DB08907
    ApprovedInvestigational

    Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897]. … Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise

    Mixtures: VOKANAMET TM TABLETAS RECUBIERTAS 50 / 1000MG, VOKANAMET ® TM_TABLETAS RECUBIERTAS 150/1000 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  7. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    Intrinsic factor (IF), also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells of the stomach that is necessary for the absorption of vitamin B12 (cobalamin) later … However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias

    Mixtures: TL-Icon
  8. Drug

    Dihydrocodeine

    go.drugbank.com/drugs/DB01551
    ApprovedIllicit

    Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis

    Mixtures: Panlor SS, J-cof DhcCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates
  9. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    Azetukalner is a small molecule drug. The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel. … Azetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da.

  10. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: SAMEXID® 50MG, SAMEXID® 30 MG